ACAD
ACADIA Pharmaceuticals Inc.$26.74-0.77 (-2.80%)Prev Close$27.52·MCap$4.80B·P/E12.15·Vol673.0K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
17
$3.40M
◆
Net Activity
Net Seller
$3.40M
●
Active Insiders
6
last 12 mo
Over the past 12 months, insider activity at ACADIA Pharmaceuticals Inc. (ACAD) has been exclusively selling, with 0 insider purchases totaling $0.00 and 17 insider sales totaling $3.40M. The most recent insider transaction was by Schneyer Mark C. (officer: EVP, CHIEF FINANCIAL OFFICER), who sold $587.2K worth of shares on Aug 7, 2026. ACADIA Pharmaceuticals Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $4.80B.
ACAD Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Aug 7, 2026 | Schneyer Mark C. | officer: EVP, CHIEF FINANCIAL OFFICER | Sell | 20,141 | $29.16 | $587.2K | 77,120 |
| Jul 31, 2026 | Thompson Elizabeth H.Z. | officer: EVP, Head of Research & Dev | Sell | 16,558 | $26.13 | $432.7K | 19,044-47% |
| Jun 29, 2026 | Kihara James | officer: PRINCIPAL ACCOUNTING OFFICER | Sell | 11,421 | $26.08 | $297.9K | 13,088-47% |
| May 27, 2026 | Kihara James | officer: PRINCIPAL ACCOUNTING OFFICER | Sell | 5,401 | $21.18 | $114.4K | 24,509 |
| May 5, 2026 | Schneyer Mark C. | officer: EVP, CHIEF FINANCIAL OFFICER | Sell | 3,506 | $21.79 | $76.4K | 66,145 |
| May 5, 2026 | Kihara James | officer: PRINCIPAL ACCOUNTING OFFICER | Sell | 1,332 | $21.79 | $29.0K | 29,129 |
| Apr 7, 2026 | Schneyer Mark C. | officer: EVP, CHIEF FINANCIAL OFFICER | Sell | 2,709 | $22.20 | $60.1K | 62,836 |
| Apr 7, 2026 | Kihara James | officer: PRINCIPAL ACCOUNTING OFFICER | Sell | 1,030 | $22.20 | $22.9K | 27,865 |
| Mar 26, 2026 | Schneyer Mark C. | officer: EVP, CHIEF FINANCIAL OFFICER | Sell | 7,385 | $21.55 | $159.1K | 60,306 |
| Mar 26, 2026 | Thompson Elizabeth H.Z. | officer: EVP, Head of Research & Dev | Sell | 3,435 | $21.47 | $73.7K | 3,280-51% |
| Mar 26, 2026 | Owen Adams Catherine | director, officer: Chief Executive Officer | Sell | 11,641 | $21.47 | $249.9K | 14,803-44% |
| Mar 26, 2026 | Rhodes Jennifer J | officer: EVP, CHIEF LEGAL OFFICER, SEC | Sell | 3,844 | $21.47 | $82.5K | 11,280-25% |
| Mar 26, 2026 | Kihara James | officer: PRINCIPAL ACCOUNTING OFFICER | Sell | 1,942 | $21.57 | $41.9K | 26,897 |
| Feb 6, 2026 | Rhodes Jennifer J | EVP, CHIEF LEGAL OFFICER, SEC | Sell | 6,950 | $23.38 | $162.5K | 0 |
| Nov 17, 2025 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 4,084 | $23.69 | $96.8K | 0 |
| Nov 17, 2025 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 10,262 | $23.69 | $243.1K | 0 |
| Nov 10, 2025 | Daly James M | Director | Sell | 30,000 | $22.37 | $671.0K | 0 |
| Sep 12, 2025 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 3,498 | $23.65 | $82.7K | 0 |
| Sep 2, 2025 | GAROFALO ELIZABETH A. | Director | Sell | 1,600 | $25.98 | $41.6K | 0 |
| Aug 18, 2025 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 22,000 | $25.18 | $554.0K | 0 |
| Jun 4, 2025 | Brege Laura | Director | Sell | 14,446 | $21.78 | $314.6K | 0 |
| May 16, 2025 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 4,000 | $22.50 | $90.0K | 0 |
| May 1, 2025 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 1,327 | $14.60 | $19.4K | 0 |
| May 1, 2025 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 3,498 | $14.60 | $51.1K | 0 |
| Apr 5, 2025 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 1,028 | $14.82 | $15.2K | 0 |
| Apr 5, 2025 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 2,708 | $14.82 | $40.1K | 0 |
| Mar 24, 2025 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 1,095 | $17.05 | $18.7K | 0 |
| Mar 24, 2025 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 3,171 | $17.05 | $54.1K | 0 |
| Mar 5, 2025 | GAROFALO ELIZABETH A. | Director | Sell | 4,919 | $18.23 | $89.7K | 0 |
| Feb 23, 2025 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 475 | $19.96 | $9.5K | 0 |
| Feb 23, 2025 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 773 | $19.96 | $15.4K | 0 |
| Nov 19, 2024 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 4,073 | $16.81 | $68.5K | 19,863 |
| Nov 19, 2024 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 10,259 | $16.81 | $172.5K | 53,302 |
| Nov 19, 2024 | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | Sell | 10,329 | $16.81 | $173.6K | 62,105 |
| Aug 20, 2024 | DAVIS STEPHEN | CEO | Sell | 31,747 | $15.28 | $485.1K | 186,555 |
| Aug 20, 2024 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 9,733 | $15.28 | $148.7K | 43,735 |
| Aug 20, 2024 | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | Sell | 9,534 | $15.28 | $145.7K | 52,177 |
| Jun 11, 2024 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 975 | $14.79 | $14.4K | 34,564 |
| May 3, 2024 | DAVIS STEPHEN | CEO | Sell | 11,427 | $16.94 | $193.6K | 155,231 |
| May 3, 2024 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 1,326 | $16.94 | $22.5K | 14,370 |
| May 3, 2024 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 3,503 | $16.94 | $59.3K | 32,053 |
| May 3, 2024 | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | Sell | 3,477 | $16.94 | $58.9K | 42,133 |
| Apr 9, 2024 | DAVIS STEPHEN | CEO | Sell | 26,574 | $17.87 | $474.9K | 161,983 |
| Apr 9, 2024 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 1,790 | $17.87 | $32.0K | 13,862 |
| Apr 9, 2024 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 2,716 | $17.87 | $48.5K | 28,742 |
| Apr 9, 2024 | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | Sell | 2,568 | $17.87 | $45.9K | 38,796 |
| Mar 27, 2024 | DAVIS STEPHEN | CEO | Sell | 17,714 | $17.90 | $317.1K | 118,842 |
| Mar 27, 2024 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 5,434 | $17.90 | $97.3K | 26,183 |
| Mar 27, 2024 | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | Sell | 5,140 | $17.90 | $92.0K | 36,340 |
| Feb 27, 2024 | DAVIS STEPHEN | CEO | Sell | 5,577 | $24.67 | $137.6K | 101,890 |
Showing 1–50 of 117
1 / 3
ACAD Insider Buying Activity
The following table shows recent insider purchases of ACADIA Pharmaceuticals Inc. (ACAD) stock reported via SEC Form 4 filings.
No insider buying activity found for ACAD in the last 12 months.
ACAD Insider Selling Activity
The following table shows recent insider sales of ACADIA Pharmaceuticals Inc. (ACAD) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Aug 7, 2026 | Schneyer Mark C. | officer: EVP, CHIEF FINANCIAL OFFICER | Sell | 20,141 | $29.16 | $587.2K | 77,120 |
| Jul 31, 2026 | Thompson Elizabeth H.Z. | officer: EVP, Head of Research & Dev | Sell | 16,558 | $26.13 | $432.7K | 19,044-47% |
| Jun 29, 2026 | Kihara James | officer: PRINCIPAL ACCOUNTING OFFICER | Sell | 11,421 | $26.08 | $297.9K | 13,088-47% |
| May 27, 2026 | Kihara James | officer: PRINCIPAL ACCOUNTING OFFICER | Sell | 5,401 | $21.18 | $114.4K | 24,509 |
| May 5, 2026 | Schneyer Mark C. | officer: EVP, CHIEF FINANCIAL OFFICER | Sell | 3,506 | $21.79 | $76.4K | 66,145 |
| May 5, 2026 | Kihara James | officer: PRINCIPAL ACCOUNTING OFFICER | Sell | 1,332 | $21.79 | $29.0K | 29,129 |
| Apr 7, 2026 | Schneyer Mark C. | officer: EVP, CHIEF FINANCIAL OFFICER | Sell | 2,709 | $22.20 | $60.1K | 62,836 |
| Apr 7, 2026 | Kihara James | officer: PRINCIPAL ACCOUNTING OFFICER | Sell | 1,030 | $22.20 | $22.9K | 27,865 |
| Mar 26, 2026 | Schneyer Mark C. | officer: EVP, CHIEF FINANCIAL OFFICER | Sell | 7,385 | $21.55 | $159.1K | 60,306 |
| Mar 26, 2026 | Thompson Elizabeth H.Z. | officer: EVP, Head of Research & Dev | Sell | 3,435 | $21.47 | $73.7K | 3,280-51% |
| Mar 26, 2026 | Owen Adams Catherine | director, officer: Chief Executive Officer | Sell | 11,641 | $21.47 | $249.9K | 14,803-44% |
| Mar 26, 2026 | Rhodes Jennifer J | officer: EVP, CHIEF LEGAL OFFICER, SEC | Sell | 3,844 | $21.47 | $82.5K | 11,280-25% |
| Mar 26, 2026 | Kihara James | officer: PRINCIPAL ACCOUNTING OFFICER | Sell | 1,942 | $21.57 | $41.9K | 26,897 |
| Feb 6, 2026 | Rhodes Jennifer J | EVP, CHIEF LEGAL OFFICER, SEC | Sell | 6,950 | $23.38 | $162.5K | 0 |
| Nov 17, 2025 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 4,084 | $23.69 | $96.8K | 0 |
| Nov 17, 2025 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 10,262 | $23.69 | $243.1K | 0 |
| Nov 10, 2025 | Daly James M | Director | Sell | 30,000 | $22.37 | $671.0K | 0 |
| Sep 12, 2025 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 3,498 | $23.65 | $82.7K | 0 |
| Sep 2, 2025 | GAROFALO ELIZABETH A. | Director | Sell | 1,600 | $25.98 | $41.6K | 0 |
| Aug 18, 2025 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 22,000 | $25.18 | $554.0K | 0 |
| Jun 4, 2025 | Brege Laura | Director | Sell | 14,446 | $21.78 | $314.6K | 0 |
| May 16, 2025 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 4,000 | $22.50 | $90.0K | 0 |
| May 1, 2025 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 1,327 | $14.60 | $19.4K | 0 |
| May 1, 2025 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 3,498 | $14.60 | $51.1K | 0 |
| Apr 5, 2025 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 1,028 | $14.82 | $15.2K | 0 |
| Apr 5, 2025 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 2,708 | $14.82 | $40.1K | 0 |
| Mar 24, 2025 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 1,095 | $17.05 | $18.7K | 0 |
| Mar 24, 2025 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 3,171 | $17.05 | $54.1K | 0 |
| Mar 5, 2025 | GAROFALO ELIZABETH A. | Director | Sell | 4,919 | $18.23 | $89.7K | 0 |
| Feb 23, 2025 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 475 | $19.96 | $9.5K | 0 |
| Feb 23, 2025 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 773 | $19.96 | $15.4K | 0 |
| Nov 19, 2024 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 4,073 | $16.81 | $68.5K | 19,863 |
| Nov 19, 2024 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 10,259 | $16.81 | $172.5K | 53,302 |
| Nov 19, 2024 | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | Sell | 10,329 | $16.81 | $173.6K | 62,105 |
| Aug 20, 2024 | DAVIS STEPHEN | CEO | Sell | 31,747 | $15.28 | $485.1K | 186,555 |
| Aug 20, 2024 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 9,733 | $15.28 | $148.7K | 43,735 |
| Aug 20, 2024 | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | Sell | 9,534 | $15.28 | $145.7K | 52,177 |
| Jun 11, 2024 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 975 | $14.79 | $14.4K | 34,564 |
| May 3, 2024 | DAVIS STEPHEN | CEO | Sell | 11,427 | $16.94 | $193.6K | 155,231 |
| May 3, 2024 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 1,326 | $16.94 | $22.5K | 14,370 |
| May 3, 2024 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 3,503 | $16.94 | $59.3K | 32,053 |
| May 3, 2024 | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | Sell | 3,477 | $16.94 | $58.9K | 42,133 |
| Apr 9, 2024 | DAVIS STEPHEN | CEO | Sell | 26,574 | $17.87 | $474.9K | 161,983 |
| Apr 9, 2024 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 1,790 | $17.87 | $32.0K | 13,862 |
| Apr 9, 2024 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 2,716 | $17.87 | $48.5K | 28,742 |
| Apr 9, 2024 | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | Sell | 2,568 | $17.87 | $45.9K | 38,796 |
| Mar 27, 2024 | DAVIS STEPHEN | CEO | Sell | 17,714 | $17.90 | $317.1K | 118,842 |
| Mar 27, 2024 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 5,434 | $17.90 | $97.3K | 26,183 |
| Mar 27, 2024 | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | Sell | 5,140 | $17.90 | $92.0K | 36,340 |
| Feb 27, 2024 | DAVIS STEPHEN | CEO | Sell | 5,577 | $24.67 | $137.6K | 101,890 |
ACAD Insiders
Owen Adams Catherine
director, officer: Chief Executive Officer
Sold $249.9K
1 tradesLast: Mar 26, 2026
Similar Stocks to ACAD
VRTX
Vertex Pharmaceuticals Incorporated
$513.52-1.17%
$132.26B
REGN
Regeneron Pharmaceuticals, Inc.
$772.87-2.63%
$83.21B
MRNA
Moderna, Inc.
$142.93-2.49%
$57.13B
RVMD
Revolution Medicines, Inc.
$204.47-0.31%
$44.15B
INSM
Insmed Incorporated
$119.56-4.63%
$28.05B
INCY
Incyte Corporation
$121.65-0.43%
$24.62B
UTHR
United Therapeutics Corporation
$500.44-0.42%
$21.10B
NBIX
Neurocrine Biosciences, Inc.
$150.44-4.31%
$15.71B